Evidence map›Paper›PMID 30833583›Full record

ArticleScientific reports2019

Stefania Croci, Alex Manicardi, Sara Rubagotti, Martina Bonacini, Michele Iori, Pier Cesare Capponi, Gianfranco Cicoria, Maria Parmeggiani, Carlo Salvarani, Annibale Versari and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. PNA-Based MicroRNA Detection Methodologies.Molecules (Basel, Switzerland) · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Stefania CrociClinical Immunology, Allergy, and Advanced Biotechnologies Unit, Diagnostic Imaging and Laboratory Medicine Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.ORCID 0000-0002-8622-0439
Alex ManicardiDepartment of Chemistry, Live Sciences and Environmental Sustainability, University of Parma, Parco Area delle Scienze, Parma, 43124, Italy.ORCID 0000-0003-0083-1392
Sara RubagottiNuclear Medicine Unit, Oncology and Advanced Technologies Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Martina BonaciniClinical Immunology, Allergy, and Advanced Biotechnologies Unit, Diagnostic Imaging and Laboratory Medicine Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Michele IoriNuclear Medicine Unit, Oncology and Advanced Technologies Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Pier Cesare CapponiNuclear Medicine Unit, Oncology and Advanced Technologies Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Gianfranco CicoriaMedical Physics Department, University Hospital "S. Orsola-Malpighi", 40138, Bologna, Italy.ORCID 0000-0001-6287-3059
Maria ParmeggianiClinical Immunology, Allergy, and Advanced Biotechnologies Unit, Diagnostic Imaging and Laboratory Medicine Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Carlo SalvaraniRheumatology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Annibale VersariNuclear Medicine Unit, Oncology and Advanced Technologies Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy.
Roberto CorradiniDepartment of Chemistry, Live Sciences and Environmental Sustainability, University of Parma, Parco Area delle Scienze, Parma, 43124, Italy.
Mattia AstiNuclear Medicine Unit, Oncology and Advanced Technologies Department, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123, Reggio Emilia, Italy. asti.mattia@ausl.re.it.ORCID 0000-0001-7564-7405
Azienda Sanitaria Unità Locale di Reggio Emilia · ITUniversity of Parma · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITUniversity of Modena and Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MiRNAs are single stranded RNAs of 18-22 nucleotides. They are promising diagnostic and prognostic markers for several pathologies including tumors, neurodegenerative, cardiovascular and autoimmune diseases. In the present work the development and characterization of anti-miRNA radiolabeled probes based on peptide nucleic acids (PNAs) for potential non-invasive molecular imaging in vivo of giant cell arteritis are described. MiR-146a and miR-146b-5p were selected as targets because they have been found up-regulated in this disease. Anti-miR and scramble PNAs were synthesized and linked to carboxyfluorescein or DOTA. DOTA-anti-miR PNAs were then labelled with copper-64 (

Indexed as

A549 CellsAntisense Elements (Genetics)Cell Line, TumorCopper RadioisotopesDiagnostic ImagingFluoresceinGiant Cell ArteritisHumansMicroRNAsPeptide Nucleic AcidsPositron-Emission TomographyRNA, AntisenseAntisense Elements (Genetics)Copper RadioisotopesFluoresceinMicroRNAsMIRN146 microRNA, humanPeptide Nucleic AcidsRNA, Antisense

Identifiers

PMID30833583
PMCPMC6399270
OpenAlexW2921769925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.